Explore more publications!
Healthcare Examiner Turks & Caicos
Got News to Share?

Healthcare Examiner Turks & Caicos: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Examiner Turks & Caicos.

September 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Press releases published on September 16, 2025

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention
September 16, 2025

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

Indeterminate GlobeNewswire
Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy
September 16, 2025

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Indeterminate GlobeNewswire
SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market
September 16, 2025

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

Indeterminate GlobeNewswire
KFSHRC réduit de 75 % le temps d’attente aux urgences pour obtenir une hospitalisation
September 16, 2025

KFSHRC réduit de 75 % le temps d’attente aux urgences pour obtenir une hospitalisation

Indeterminate GlobeNewswire
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
September 16, 2025

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

Indeterminate GlobeNewswire
SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial
September 16, 2025

SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial

Indeterminate GlobeNewswire
Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo
September 16, 2025

Hyperion DeFi Enters Into First HAUS Agreement With Proprietary Trading Firm Credo

Indeterminate GlobeNewswire
Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™
September 16, 2025

Medicines360 acquires global rights to PeriPeach™, advancing new maternal health technology through the 360 Innovation Hub™

Indeterminate GlobeNewswire
Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD
September 16, 2025

Starton Therapeutics Granted New U.S. Patent #12,390,457 Titled “Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use” a Formulation of STAR-LLD

Indeterminate GlobeNewswire
Parexel Announces Appointment of Rob Goodwin as Chief Operating Officer
September 16, 2025

Parexel Announces Appointment of Rob Goodwin as Chief Operating Officer

Indeterminate GlobeNewswire
ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant
September 16, 2025

ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant

Indeterminate GlobeNewswire
Marine Biologics Partners with Molecular Quantum Solutions to Accelerate Next-Generation Biomaterials Development
September 16, 2025

Marine Biologics Partners with Molecular Quantum Solutions to Accelerate Next-Generation Biomaterials Development

Indeterminate GlobeNewswire
Highridge Medical Enters Exclusive Distribution Agreement for the PathKeeper Surgical Navigation System
September 16, 2025

Highridge Medical Enters Exclusive Distribution Agreement for the PathKeeper Surgical Navigation System

Indeterminate GlobeNewswire
Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation
September 16, 2025

Elutia Announces Newly Published Clinical Data Demonstrating that Biologic Envelopes Support CIED Stabilization and Ease of Reoperation

Indeterminate GlobeNewswire
Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
September 16, 2025

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Indeterminate GlobeNewswire
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
September 16, 2025

Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04

Indeterminate GlobeNewswire
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
September 16, 2025

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

Indeterminate GlobeNewswire
Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate
September 16, 2025

Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate

Indeterminate GlobeNewswire
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
September 16, 2025

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

Indeterminate GlobeNewswire
Hop Valley Brewing and Oregon Athletics Announce the Launch of Dang Green IPA, the First Official Craft Beer for the Oregon Ducks
September 16, 2025

Hop Valley Brewing and Oregon Athletics Announce the Launch of Dang Green IPA, the First Official Craft Beer for the Oregon Ducks

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions